Log In
BCIQ
Print this Print this
 

Triplex

  Manage Alerts
Collapse Summary General Information
Company Helocyte Inc.
DescriptionUniversal peptide vaccine composed of human cytomegalovirus (CMV) phosphoprotein 65 (pp65; UL183), IE4 and IE5 antigens
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsControl cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients
Regulatory Designation
PartnerCity of Hope;
Fortress Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.0M

0

0


 Deals Details
Get a free BioCentury trial today